Its revenue elevated by 5%, to 744 million, supported by its acquisition of the HRA firm, specialised in uncommon learn ailments
https://www.elmundo.es/economia/empresas/2025/05/14/6824a341fc6c8394418b458d.html
The Catalan Pharmaceutical Esteve raised its advantages by 23% in 2024, to achieve 75 million euros | EUROtoday
